MG
NGM

Michael Gelband’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Michael Gelband’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-107,214
Closed -$538K – 2211
2022
Q4 		$538K Buy
107,214
+54,542
+104% +$342K 0.01% 1144
2022
Q3 		$689K Buy
+52,672
New +$798K 0.01% 1255
2022
Q1 		– Sell
-20,393
Closed -$361K – 2783
2021
Q4 		$361K Buy
+20,393
New +$391K ﹤0.01% 1585
2019
Q4 		– Sell
-17,400
Closed -$241K – 1976
2019
Q3 		$241K Buy
+17,400
New +$261K 0.01% 1019

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Michael Gelband's NGM Position: Q1 2023 in Review

Michael Gelband sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 107,214 shares — an estimated $538K sold.

Michael Gelband first reported a position in NGM in Q3 2019 and held it in 4 quarters. The position peaked at $689K in Q3 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

  • Michael Gelband reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Michael Gelband sold 107,214 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $538K.
  • Michael Gelband first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Michael Gelband's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $689K in Q3 2022.
  • 122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.